| pubmed-article:16500924 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16500924 | lifeskim:mentions | umls-concept:C1280551 | lld:lifeskim |
| pubmed-article:16500924 | lifeskim:mentions | umls-concept:C0205527 | lld:lifeskim |
| pubmed-article:16500924 | lifeskim:mentions | umls-concept:C0027934 | lld:lifeskim |
| pubmed-article:16500924 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
| pubmed-article:16500924 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:16500924 | lifeskim:mentions | umls-concept:C0599894 | lld:lifeskim |
| pubmed-article:16500924 | lifeskim:mentions | umls-concept:C1521840 | lld:lifeskim |
| pubmed-article:16500924 | lifeskim:mentions | umls-concept:C1172252 | lld:lifeskim |
| pubmed-article:16500924 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:16500924 | pubmed:dateCreated | 2006-4-10 | lld:pubmed |
| pubmed-article:16500924 | pubmed:abstractText | Intrathecal (IT) substance P-Saporin (SP-SAP), a 33-kDa-targeted neurotoxin, produces selective destruction of superficial neurokinin 1 receptor (NK1r)-bearing cells in the spinal dorsal horn. In rats, SP-SAP prevents the formation of hyperalgesia and can reverse established neuropathic pain behavior in rodents. To determine the safety of this therapeutic modality in a large animal model, beagles received bolus IT lumbar injections of vehicle, SP-SAP (1.5, 15, 45, or 150 microg), or a nontargeted preparation of saporin (SAP, 150 microg) for immunohistological analysis of spinal cords. Doses of 15 microg SP-SAP and above produced a significant and equivalent loss of NK1r-bearing cells and dendrites in lumbar laminae II and I compared to vehicle- or SAP-treated animals. Cervical regions in all animals displayed no loss of NK1r immunoreactivity as compared to controls. Total numbers of neurons in the lumbar dorsal horn or alpha-motor neurons in the ventral horn demonstrated no significant changes. No increases in the astrocytic marker glial fibrillary acidic protein were noted following treatment with SP-SAP, suggesting a lack of generalized neurotoxicity. Additional dogs received doses of 1.5-150 microg SP-SAP or SAP and were sacrificed after 28 or 90 days to assess behavioral and physiological parameters. Although some acute motor signs were observed with both SP-SAP and SAP, no long-lasting significant events were noted in any of these animals. These data indicate no adverse toxicity at doses up to 10 times those necessary for producing loss of superficial NK1r-bearing neurons in a large animal model. | lld:pubmed |
| pubmed-article:16500924 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16500924 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16500924 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16500924 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16500924 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16500924 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16500924 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16500924 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16500924 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16500924 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16500924 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16500924 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16500924 | pubmed:month | May | lld:pubmed |
| pubmed-article:16500924 | pubmed:issn | 1096-6080 | lld:pubmed |
| pubmed-article:16500924 | pubmed:author | pubmed-author:YakshTony LTL | lld:pubmed |
| pubmed-article:16500924 | pubmed:author | pubmed-author:RogersScott... | lld:pubmed |
| pubmed-article:16500924 | pubmed:author | pubmed-author:MantyhPatrick... | lld:pubmed |
| pubmed-article:16500924 | pubmed:author | pubmed-author:GrafeMarjorie... | lld:pubmed |
| pubmed-article:16500924 | pubmed:author | pubmed-author:GhilardiJosep... | lld:pubmed |
| pubmed-article:16500924 | pubmed:author | pubmed-author:AllenJeffrey... | lld:pubmed |
| pubmed-article:16500924 | pubmed:author | pubmed-author:CizkovaDasaD | lld:pubmed |
| pubmed-article:16500924 | pubmed:author | pubmed-author:HoraisKjersti... | lld:pubmed |
| pubmed-article:16500924 | pubmed:author | pubmed-author:LappiDouglas... | lld:pubmed |
| pubmed-article:16500924 | pubmed:author | pubmed-author:TozierNicoleN | lld:pubmed |
| pubmed-article:16500924 | pubmed:author | pubmed-author:RichterPhilli... | lld:pubmed |
| pubmed-article:16500924 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16500924 | pubmed:volume | 91 | lld:pubmed |
| pubmed-article:16500924 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16500924 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16500924 | pubmed:pagination | 286-98 | lld:pubmed |
| pubmed-article:16500924 | pubmed:dateRevised | 2010-9-17 | lld:pubmed |
| pubmed-article:16500924 | pubmed:meshHeading | pubmed-meshheading:16500924... | lld:pubmed |
| pubmed-article:16500924 | pubmed:meshHeading | pubmed-meshheading:16500924... | lld:pubmed |
| pubmed-article:16500924 | pubmed:meshHeading | pubmed-meshheading:16500924... | lld:pubmed |
| pubmed-article:16500924 | pubmed:meshHeading | pubmed-meshheading:16500924... | lld:pubmed |
| pubmed-article:16500924 | pubmed:meshHeading | pubmed-meshheading:16500924... | lld:pubmed |
| pubmed-article:16500924 | pubmed:meshHeading | pubmed-meshheading:16500924... | lld:pubmed |
| pubmed-article:16500924 | pubmed:meshHeading | pubmed-meshheading:16500924... | lld:pubmed |
| pubmed-article:16500924 | pubmed:meshHeading | pubmed-meshheading:16500924... | lld:pubmed |
| pubmed-article:16500924 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16500924 | pubmed:articleTitle | Safety evaluation of intrathecal substance P-saporin, a targeted neurotoxin, in dogs. | lld:pubmed |
| pubmed-article:16500924 | pubmed:affiliation | Department of Anesthesiology, University of California, San Diego, La Jolla, California 92093-0818, USA. | lld:pubmed |
| pubmed-article:16500924 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16500924 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| pubmed-article:16500924 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:16500924 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16500924 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16500924 | lld:pubmed |
